new data from alphamab oncology’s kn046 and kn026 to be presented at the esmo congress 2021-凯发vip

english 中文简体 中文繁体

new data from alphamab oncology’s kn046 and kn026 to be presented at the esmo congress 2021

july 26, 2021 08:35 eastern daylight time

suzhou, july 26, 2021 - alphamab oncology (stock code: 9966.hk) announced, data from three clinical studies of kn046 (pd-l1/ctla4 bispecific antibody) and kn026 (anti-her2 bispecific antibody) will be presented in three e-posters at the esmo congress 2021, to be held virtually from september 16th to september 21st.

 

title:

kn046 (an anti-pd-l1/ctla-4 bispecific antibody) in combination with lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (hcc): preliminary efficacy and safety results of a prospective phase ii trial

poster number: 938p

presentation format: e-poster

first author: professor bao-cai xing, beijing cancer hospital

abstract release time: 00:05 cest on september 13, 2021

 

title:

preliminary efficacy and safety results of kn026 (a her2-targeted bispecific antibody) in combination with kn046 (an anti-pd-l1/ctla-4 bispecific antibody) in patients (pts) with her2-positive gastrointestinal tumors

poster number: 1377p

presentation format: e-poster

first author: professor jifang gong, beijing cancer hospital

abstract release time: 00:05 cest on september 13, 2021

 

title:

kn046 (an anti-pd-l1/ctla-4 bispecific antibody) in combination with platinum doublet chemotherapy as first-line(1l) treatment in patients with advanced nsclc harboring resistant oncogenic driver alterations

poster number: 1293p

presentation format: e-poster

first author: professor wenfeng fang, sun yat-sen university cancer center

abstract release time: 00:05 cest on september 13, 2021

 

about kn046

kn046 is pd-l1/ctla-4 bispecific antibody independently developed by jiangsu alphamab. its innovative designs include: a different mechanism ctla-4 fused with pd-l1 single domain antibody; engineered to target the tumor microenvironment with high pd-l1 expression, and treg(suppress tumor immunity) clearing function.

 

there are about 20 clinical trials of kn046 in different stages covering more than 10 types of tumors including nsclc, tnbc, escc, hcc and pancreatic cancer in australia and china. the results of these clinical trials have shown an advantage in survival for patients. alphamab has received fda clearance to enter phase ⅱ trial of kn046 based on the clinical results in china and australia. moreover, kn046 has obtained the u.s. fda's orphan drug designation for thymic epithelial tumor in september 2020. four pivotal clinical trials are currently being conducted.

 

about kn026

kn026 is an anti-her2 bispecific antibody developed by alphamab oncology using the proprietary fc-based heterodimer bispecific platform technology called crib (charge repulsion induced bispecific). kn026 can bind two non-overlapping epitopes of her2 simultaneously, leading to a dual her2 signal blockade. kn026 has demonstrated potentially equivalent efficacy compared with trastuzumab and pertuzumab alone or in combination, such as increased binding affinity, as well as better tumor inhibition in her2-positive tumor cell lines. additionally, kn026 has also shown inhibitory effect on tumor cells with medium or low her2 expression or trastuzumab-resistant cell lines.

 

kn026 received ind approval from the national medical products administration (nmpa) of china and u.s. food and drug administration (fda) in 2018. currently, it is in multiple phase i/ii clinical trials in china and phase i clinical trial in the united states. the results of phase i clinical trials show kn026 has excellent safety, tolerance and potentially superior anti-tumor activity in her2-positive breast cancer patients who progressed after multiple lines of anti-her2 treatment.

 

about alphamab oncology

alphamab oncology is focusing on innovation, production and commercialization of anti-tumor drugs. on december 12, 2019, the company was listed in the mainboard of hong kong stock exchange with stock code 9966.

 

alphamab has fully integrated proprietary biologics platforms in bi-specifics and protein engineering. its highly differentiated in-house pipeline includes fifteen tumor monoclonal antibodies and bispecific antibodies and a covid-19 multifunctional antibody. four products have advanced into phase i-iii clinical trials or pre-marketing stage in china, the united states, japan and australia. the bla for envafolimab (kn035) has been accepted and granted priority review by the national medical products administration (nmpa).

 

the company also has state-of-the-art manufacturing capabilities designed and built to meet nmpa and eu/fda’s cgmp standards and a complete quality system which has passed the on-site inspection of a european union qualified person. alphamab oncology is committed to building a global leading, multi-dimensional drug development and commercialization platform, focusing on multifunctional biological innovative drugs, and to benefit patients in china and around the world.

 

alphamab oncology forward-looking statements

this press release contains statements related to our future business and financial performance and future events or developments involving alphamab oncology that may constitute forward-looking statements. these statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. these statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. we may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. in addition, our representatives may from time to time make oral forward-looking statements. such statements are based on the current expectations and certain assumptions of alphamab oncology’s management and business operation, many of which are difficult to predict and generally beyond alphamab oncology’s control. these are subject to a number of risks and uncertainties, including but not limited to, uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, alphamab oncology's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding and alphamab oncology’s disclosures. should one or more of these risks or uncertainties materialize or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of alphamab oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. other than as required by applicable law, alphamab oncology undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.